Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 08 Jun 2022
Vertex announces inaxaplin (VX-147) granted breakthrough therapy designation by U.S. FDA and PRIME designation by the EMA
8 June 2022 - Vertex granted nine breakthrough therapy designations and three PRIME designations across its pipeline programs to date. ...
Posted by Michael Wonder on 08 Jun 2022
The UK MHRA, Australian TGA and Health Canada approve Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
8 June 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall survival ...
Posted by Michael Wonder on 08 Jun 2022
FDA grants fast track designation for BioCryst’s ALK-2 inhibitor, BCX9250
8 June 2022 - BioCryst Pharmaceuticals today announced the U.S. FDA has granted fast track designation for BCX9250 for the ...
Posted by Michael Wonder on 08 Jun 2022
Updated price disclosure guidelines, price disclosure webpages and price disclosure dispute resolution process
8 June 2022 - Amendments made to the National Health Act 1953 and National Health (Pharmaceutical Benefits) Regulations 2017 by the ...
Posted by Michael Wonder on 08 Jun 2022
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
6 June 2022 - Sugemalimab became the first anti-PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC following concurrent or sequential chemoradiotherapy. ...
Posted by Michael Wonder on 08 Jun 2022
PHARMAC says funding Trikafta would take 'almost all' new money
8 June 2022 - PHARMAC's chairman says funding the cystic fibrosis drug Trikafta would swallow nearly all the new money ...
Posted by Michael Wonder on 08 Jun 2022
Another new month, another terminated NICE appraisal
8 June 2022 - This time it is not for a cancer medicine. ...
Posted by Michael Wonder on 08 Jun 2022
BioCryst announces approval of Orladeyo (berotralstat) by Swissmedic
7 June 2022 - -- BioCryst Pharmaceuticals today announced that Swissmedic has granted marketing authorisation for oral, once-daily Orladeyo (berotralstat) ...
Posted by Michael Wonder on 08 Jun 2022
Forus Therapeutics announces Xpovio (selinexor) is authorised for sale by Health Canada
7 June 2022 - FORUS Therapeutics is pleased to announce that on 31 May 2022, Xpovio (selinexor) was authorised for ...
Posted by Michael Wonder on 07 Jun 2022
Trends in prescription drug launch prices (2008-2021)
7 June 2022 - Prescription drug spending in the US exceeded half a trillion dollars in 2020. ...
Posted by Michael Wonder on 07 Jun 2022
FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate to severe atopic dermatitis
7 June 2022 - Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy ...
Posted by Michael Wonder on 07 Jun 2022
FDA approves drug for prevention of organ rejection in paediatric recipients of heart and liver transplants
7 June 2022 - The FDA has expanded the use of CellCept (mycophenolate mofetil) to prophylaxis of organ rejection in ...
Posted by Michael Wonder on 07 Jun 2022
Global expert panel publishes guidance on deliberative processes for health technology assessment
7 June 2022 - Value in Health announced today the publication of guidance regarding the establishment or improvement of deliberative ...
Posted by Michael Wonder on 07 Jun 2022
Japan drug maker tests medicine vending machine in train station
4 June 2022 - A Japanese pharmaceutical company has started a trial sale of cold medicine, painkillers and other drugs via ...
Posted by Michael Wonder on 07 Jun 2022
U.S. probes how pharmacies set drug prices as costs rise
7 June 2022 - The U.S. Federal Trade Commission has opened a probe into how big pharmacy benefit managers like ...